Dr. Thompson’s Lab published a study on different Beta Cells dysfunction and their respective therapeutic targets in preventing Type 1 Diabetes: “We discuss opportunities and important open questions around the effectiveness of beta cell therapies and challenges for clinical utility. We further evaluate ways in which beta cell drug therapy could be combined with immunotherapy for preventing T1D in light of our growing appreciation of disease heterogeneity and patient endotypes.”
CLICK HERE for the full article
What's New
All Articles
CTVNews Winnipeg Interview with Dr. Brandy Wicklow
DREAM researcher Dr. Brandy Wicklow, pediatric endocrinologist at the University of Manitoba and Children’s Hospital Research Institute of Manitoba, was…
iCARE PAG Member Antonina Kandiurin Presented at ISPAD 2025
iCARE PAG member Antonina Kandiurin presented at the 51st Annual International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference held…
New publication from the Dolinsky Lab!
Congratulations to Caitlin Menzies, PhD student in Dr. Vern Dolinsky’s lab, for their newly published review in the Journal of…
FARHA Inc. Research Podcast S1E1
🎙️ The first FARHA Inc. research podcast is here! In this S1E1, St. Theresa Point’s Tanya Dawn McDougall, Anisininew scholar…
4 DREAM Researchers Receive Funding from CHRIM Operating Grants
DREAM researchers Drs. Christine Doucette, Peter Thompson, Vern Dolinsky, and Lucy Marzban have been granted close to $150,000 in funding…
New Publication from the Thompson Lab!
Congratulations to the Thompson lab on their newest publication in Diabetes Journal, led by Dr. Thompson’s amazing PhD student Jasmine…